AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03945526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT04631575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390, PO,single-dose
Study NCT00632099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone
Description: Oral micronized progesterone (up to 400 mg/day), suspended in olive oil
Study NCT00632099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT02537886 — intervention group
Intervention type: DEVICE
Intervention: Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)
Description: Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
Study NCT01397799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391
Description: Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
Study NCT03413111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified double wire technique
Description: For experimental arm, a tiny cut of papilla orifice, with the length of 5mm, was performed by sphincterotome before the double wire cannulation.
Study NCT02975895 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrophobic IOL: Vivinex (HOYA)
Description: Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
Study NCT02975895 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrophilic IOL: INCISE (Bausch+Lomb)
Description: Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
Study NCT04035447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Symptom Management for Young Adult Cancer Survivors
Description: The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
Study NCT04035447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Symptom Management for Young Adult Cancer Survivors
Description: The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
Study NCT01823042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine+enteral nutrition
Study NCT01823042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Study NCT04592640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human amniotic mesenchymal stem cells
Description: 1. Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).~2. Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).
Study NCT02690857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Study NCT02690857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Study NCT04240444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-coated balloon Catheter
Description: All eligible subjects will be assigned randomly to study group or control group, receive PTCA.
Study NCT04240444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-coated balloon Catheter
Description: All eligible subjects will be assigned randomly to study group or control group, receive PTCA.
Study NCT03804333 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions
Study NCT03804333 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 2000 cGy in 4 fractions administered twice a day
Study NCT01230307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
Study NCT01230307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
Study NCT02767440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families on Track Intervention
Description: Parents will receive the standard of care activities at the Healthy Lifestyles clinic at Duke University. They will also receive a modified version of the previously conducted Track intervention, a digital health weight loss intervention for adults in community health centers . The intervention will utilize the Interactive Obesity Treatment Approach (iOTA). iOTA uses a computer algorithm to assign 3 personalized behavioral goals known to create an energy deficit to produce weight loss (e.g., sugary drinks, fast food consumption walk 10,000 steps/day, etc). Participants will track these goals via interactive voice response (IVR) and text messaging technologies each week. They will receive immediate feedback based on self-monitoring data and skills training videos to learn how to make the behavioral changes necessary for weight loss. Intervention participants will also receive an analog bathroom scale and a pedometer to self-monitor daily weights and steps.
Study NCT01186575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Context-sensitive text messages are sent to men after undergoing circumcision
Study NCT03045679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RYGB
Description: laparoscopic RYGB
Study NCT03045679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OAGB/MGB
Description: laparoscopic OAGB/MGB
Study NCT02111161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG (Privigen)
Description: Three doses of 25 g IVIG (250 ml)
Study NCT02111161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Three doses of Saline 0.9% (250 ml)
Study NCT03172845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: percutaneous coronary intervention with drug-eluting stent implantation.
Study NCT03172845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: percutaneous coronary intervention with drug-eluting stent implantation.
Study NCT00816426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin
Description: Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
Study NCT00816426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isoniazid
Description: Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
Study NCT00816426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pyrazinamide
Description: Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
Study NCT00816426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Kanamycin
Description: Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
Study NCT00816426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
Study NCT04291443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heavy Force (225g)
Description: Orthodontic Force
Study NCT04291443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Force (25g)
Description: Orthodontic Force
Study NCT04484298 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reference position patient is put in a 30 degree supine position during 5 minutes
Description: Each patient is initially placed in a semi-sitting position at 30° for 5 minutes and then CO is measured (baseline CO)
Study NCT04484298 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nitroglucerin
Description: 0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.
Study NCT03962101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection
Description: Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
Study NCT03255681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injections into nasojugal folds
Description: A topical anesthetic consisting of 4% Lidocaine (Topicaine) will be placed in the treatment zone prior to injections for no less than 20 minutes per manufactures recommendations.~11ml of whole blood will be drawn from the patient via venous aspiration into the Eclipse collection tube. The blood then is centrifuged into three basic components: red blood cells, PRP and platelet-poor plasma. The PRP component is collected via manufactures recommendation, drawn into sterile syringes, and prepared for injection into the patient. 0.1cc of 10% CaCl2 per 1ml of PRP will be added and mixed into the PRP solution for injections on one side of the face.~Injections will be completed using Softfil micro-cannulas inserted via a small puncture through the patients' skin to dissect into the subcutaneous plane
Study NCT04070742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101
Study NCT04652323 — intervention group
Intervention type: DRUG
Intervention: Biocompatibility of calcium silicate cements
Description: The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
Study NCT03227900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intragastric infusion of lidocain
Study NCT03227900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Intragastric infusion of water for injections
Study NCT02577614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEIBA
Description: Administration of FEIBA after cardiopulmonary bypass
Study NCT02577614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administration of placebo after cardiopulmonary bypass
Study NCT01399788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrin P Forte
Description: Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
Study NCT01399788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single drug references
Description: containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
Study NCT03255707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eye patch
Description: Occluding the better seeing eye for a given number of hours daily
Study NCT03255707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dichoptic treatment
Description: dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
Study NCT00734799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention for PTSD (SIP).
Description: Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's rescripting of reoccurring nightmares to decrease their associated affective distress.
Study NCT03535467 — intervention group
Intervention type: OTHER
Intervention: Caregiver's Burden Inventory
Description: The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.
Study NCT01594515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: High dose powder for oral solution
Study NCT01594515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Medium dose powder for oral solution
Study NCT01594515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Low dose powder for oral solution
Study NCT01594515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for oral administration
Study NCT01594515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 101550
Description: High dose powder for oral solution
Study NCT04315181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Abuse liability evaluation.
Study NCT04315181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid Agonist
Description: Abuse liability evaluation.
Study NCT04315181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives
Description: Abuse liability evaluation.
Study NCT04315181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sedatives
Description: Abuse liability evaluation.
Study NCT03213964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FATE-NK100
Description: FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~* Dose Level 1: 1 x 10\^7 cells/kg IP~* Dose Level 2: >1x10\^7 cells/kg to ≤3x10\^7 cells/kg~* Dose Level 3: Complete FATE-NK100 bag (≥3 x 10\^7 to ≤ 10 x 10\^7 cells/kg)
Study NCT03213964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting.
Study NCT00595556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: flexible dosages of 100-500mg/day
Study NCT00595556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00827606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
Study NCT00794677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
Study NCT00794677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
Study NCT02567253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
Study NCT02567253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPEC with Cisplatin (75mg/m²)
Description: Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
Study NCT02567253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPEC with Cisplatin (100mg/m²)
Description: Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
Study NCT02567253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)
Description: Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
Study NCT02567253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC with Cisplatin (100mg/m²)
Description: Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
Study NCT03173794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CommunityRx-H
Description: CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources.
Study NCT04707742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine© bucal 100 mg/ml
Description: 15 ml 2% povidone-iodine, one minute rinse.
Study NCT04707742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oximen® 3%
Description: 15 ml 1% hydrogen peroxide, one minute rinse.
Study NCT04707742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clorhexidine Dental PHB©
Description: 15 ml 0,12% clorhexidine, one minute rinse.
Study NCT04707742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitis Xtra Forte©
Description: 15 ml 0,07% cetylpyridinium chloride, one minute rinse.